{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:31:10Z","timestamp":1793399470064,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Excess growth hormone, as encountered in acromegaly, promotes insulin resistance and enhances adipose tissue lipolysis. This study aimed to summarize the currently available data on the prevalence of hepatic steatosis and liver fibrosis in patients with acromegaly. The secondary objective was to map the studies on the influence of treatment modalities on hepatic outcomes in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This scoping review was conducted following the PRISMA-ScR guidelines. We performed a systematic literature search across two electronic databases: PubMed and Web of Science from their inception to the 4th of April 2026. In addition, articles were identified through manual searches using Google Scholar and citation tracking. Peer-reviewed original journal articles evaluating hepatic steatosis, fibrosis, and intracellular hepatic lipid (IHL) content in patients with acromegaly were included. Studies that did not utilize radiological methods and case reports were excluded. Results were synthesized narratively and summarized in tables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one original studies were included. High heterogeneity was observed among the studies, including study models, imaging methods, patient populations, and outcomes. The data presented in this literature review reveal a pattern of lower IHL content in active acromegaly patients but a higher likelihood of liver fibrosis compared with controls. Control of acromegaly may be associated with a rise in IHL content.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IHL content and hepatic fibrosis in patients with acromegaly may be influenced by disease control status and treatment modalities. Further high-quality studies are required to assess the risk of liver steatosis and fibrosis in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-026-02940-1","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:42:11Z","timestamp":1780569731000},"page":"3157-3171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver steatosis and fibrosis in acromegaly patients with active and controlled disease: a scoping review"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1918-4519","authenticated-orcid":false,"given":"Karol P.","family":"Sagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Lipiec-Rzepecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyna","family":"Patalong-W\u00f3jcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142 P.","family":"Wasilewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Andrysiak-Mamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhelli","family":"Syrenicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2940_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10:804\u2013826. https:\/\/doi.org\/10.1016\/S2213-8587(22)00244-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2940_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","volume":"20","author":"A Lavrentaki","year":"2017","unstructured":"Lavrentaki A, Paluzzi A, Wass JAH, Karavitaki N (2017) Epidemiology of acromegaly: review of population studies. Pituitary 20:4\u20139. https:\/\/doi.org\/10.1007\/s11102-016-0754-x","journal-title":"Pituitary"},{"key":"2940_CR3","doi-asserted-by":"publisher","first-page":"e837","DOI":"10.1161\/CIRCULATIONAHA.111.077602","volume":"124","author":"KA Britton","year":"2011","unstructured":"Britton KA, Fox CS (2011) Ectopic fat depots and cardiovascular disease. Circulation 124:e837\u2013841. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.077602","journal-title":"Circulation"},{"key":"2940_CR4","doi-asserted-by":"publisher","first-page":"bvae032","DOI":"10.1210\/jendso\/bvae032","volume":"8","author":"A Milioto","year":"2024","unstructured":"Milioto A, Corica G, Nista F, Wildemberg LEA, Rossi F, Bignotti B et al (2024) Skeletal Muscle Evaluation in Patients With Acromegaly. J Endocr Soc 8:bvae032. https:\/\/doi.org\/10.1210\/jendso\/bvae032","journal-title":"J Endocr Soc"},{"key":"2940_CR5","doi-asserted-by":"publisher","DOI":"10.5603\/ep.99689","author":"S Suwa\u0142a","year":"2024","unstructured":"Suwa\u0142a S, Junik R (2024) Metabolic-associated fatty liver disease and the role of hormones in its aetiopathogenesis. Endokrynol Pol. https:\/\/doi.org\/10.5603\/ep.99689. VM\/OJS\/J\/99689","journal-title":"Endokrynol Pol"},{"key":"2940_CR6","doi-asserted-by":"publisher","first-page":"e13695","DOI":"10.1111\/eci.13695","volume":"52","author":"S Guerra","year":"2022","unstructured":"Guerra S, Mocciaro G, Gastaldelli A (2022) Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis. Eur J Clin Invest 52:e13695. https:\/\/doi.org\/10.1111\/eci.13695","journal-title":"Eur J Clin Invest"},{"key":"2940_CR7","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52:1836\u20131846. https:\/\/doi.org\/10.1002\/hep.24001","journal-title":"Hepatology"},{"key":"2940_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA (2025) Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol 13:134\u2013148. https:\/\/doi.org\/10.1016\/S2213-8587(24)00318-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2940_CR9","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L (2025) Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol 31:S32\u201350. https:\/\/doi.org\/10.3350\/cmh.2024.0431","journal-title":"Clin Mol Hepatol"},{"key":"2940_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","volume":"9","author":"M Israelsen","year":"2024","unstructured":"Israelsen M, Torp N, Johansen S, Hansen CD, Hansen ED, Thorhauge K et al (2024) Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol 9:218\u2013228. https:\/\/doi.org\/10.1016\/S2468-1253(23)00443-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2940_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","volume":"1","author":"S Albhaisi","year":"2019","unstructured":"Albhaisi S, Chowdhury A, Sanyal AJ (2019) Non-alcoholic fatty liver disease in lean individuals. JHEP Rep 1:329\u2013341. https:\/\/doi.org\/10.1016\/j.jhepr.2019.08.002","journal-title":"JHEP Rep"},{"key":"2940_CR12","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al (2024) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol 29:101133. https:\/\/doi.org\/10.1016\/j.aohep.2023.101133","journal-title":"Ann Hepatol"},{"key":"2940_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D et al (2018) PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 169:467\u2013473. https:\/\/doi.org\/10.7326\/M18-0850","journal-title":"Ann Intern Med"},{"key":"2940_CR14","doi-asserted-by":"publisher","first-page":"e00090","DOI":"10.1002\/edm2.90","volume":"2","author":"A Koutsou-Tassopoulou","year":"2019","unstructured":"Koutsou-Tassopoulou A, Papapostoli-Sklavounou I, Krawczyk M, Friesenhahn-Ochs B, Weber SN, Lammert F et al (2019) Hepatic steatosis in patients with acromegaly. Endocrino Diabet Metabol 2:e00090. https:\/\/doi.org\/10.1002\/edm2.90","journal-title":"Endocrino Diabet Metabol"},{"issue":"14","key":"2940_CR15","doi-asserted-by":"publisher","first-page":"4822","DOI":"10.3390\/jcm14144822","volume":"8","author":"Y Karadeniz","year":"2025","unstructured":"Karadeniz Y, Karakose M (2025) Non-Invasive Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Risk in Acromegaly Indicates Persistence of Cardiac Risks Despite Biochemical Disease Control. J Clin Med Jul 8(14):4822. https:\/\/doi.org\/10.3390\/jcm14144822","journal-title":"J Clin Med"},{"key":"2940_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5421961","volume":"2018","author":"A Ciresi","year":"2018","unstructured":"Ciresi A, Guarnotta V, Campo D, Giordano C (2018) Hepatic Steatosis Index in Acromegaly: Correlation with Insulin Resistance Regardless of the Disease Control. Int J Endocrinol 2018:1\u20137. https:\/\/doi.org\/10.1155\/2018\/5421961","journal-title":"Int J Endocrinol"},{"key":"2940_CR17","doi-asserted-by":"publisher","first-page":"e14212","DOI":"10.1097\/MD.0000000000014212","volume":"98","author":"M Bankir","year":"2019","unstructured":"Bankir M, Sumbul HE, Koc AS, Demirtas D, Acibucu F (2019) Elastography detected solid organ stiffness increased in patients with acromegaly. Medicine 98:e14212. https:\/\/doi.org\/10.1097\/MD.0000000000014212","journal-title":"Medicine"},{"key":"2940_CR18","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s40618-024-02384-5","volume":"47","author":"M Coskun","year":"2024","unstructured":"Coskun M, Sendur HN, Babayeva A, Cerit MN, Cerit ET, Yalcin MM et al (2024) Quantitative ultrasound techniques and biochemical markers to assess liver steatosis and fibrosis in newly diagnosed acromegaly. J Endocrinol Invest 47:2823\u20132833. https:\/\/doi.org\/10.1007\/s40618-024-02384-5","journal-title":"J Endocrinol Invest"},{"key":"2940_CR19","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1507\/endocrj.EJ25-0047","volume":"72","author":"N Yamamoto","year":"2025","unstructured":"Yamamoto N, Urai S, Yamamoto M, Suzuki M, Tsujimoto Y, Bando H et al (2025) Body mass index and metabolic complications in individuals with treatment-na\u00efve acromegaly. Endocr J 72:1041\u20131049. https:\/\/doi.org\/10.1507\/endocrj.EJ25-0047","journal-title":"Endocr J"},{"key":"2940_CR20","doi-asserted-by":"publisher","unstructured":"Saleem S, Ahmad M, Imran Andrabi W, Naseer Syed F, Kamran A, Gulzar R et al (2023) Assessment of Liver Steatosis and Fibrosis in Newly Diagnosed Acromegaly: An Integrated Approach Utilizing Quantitative Ultrasound, Histological Analysis and Biochemical Markers. Pak J Med Health Sci 17. https:\/\/doi.org\/10.53350\/pjmhs020231711129","DOI":"10.53350\/pjmhs020231711129"},{"key":"2940_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.18663\/tjcl.604304","volume":"11","author":"A Arslan","year":"2020","unstructured":"Arslan A, Kartal Baykan E, Karauzum Yalcin N, Utlu M, Kiper Yilmaz HT, Caglar AA et al (2020) Fatty liver in patients with acromegaly. Turkish J Clin Lab 11:33\u201338. https:\/\/doi.org\/10.18663\/tjcl.604304","journal-title":"Turkish J Clin Lab"},{"key":"2940_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40618-025-02799-8","volume":"49","author":"T Apaydin","year":"2026","unstructured":"Apaydin T, Kani HT, Keklikkiran C, Yilmaz Y, Yavuz DG (2026) The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging. J Endocrinol Invest 49:1029\u20131038. https:\/\/doi.org\/10.1007\/s40618-025-02799-8","journal-title":"J Endocrinol Invest"},{"key":"2940_CR23","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1210\/clinem\/dgad490","volume":"109","author":"\u0130 Ero\u011flu","year":"2023","unstructured":"Ero\u011flu \u0130, Iremli BG, Idilman IS, Yuce D, Lay I, Akata D et al (2023) Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Utility of Noninvasive Scores in Patients With Acromegaly. J Clin Endocrinol Metabolism 109:e119\u2013e129. https:\/\/doi.org\/10.1210\/clinem\/dgad490","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2940_CR24","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1210\/jc.2017-01210","volume":"102","author":"MA Bredella","year":"2017","unstructured":"Bredella MA, Schorr M, Dichtel LE, Gerweck AV, Young BJ, Woodmansee WW et al (2017) Body Composition and Ectopic Lipid Changes With Biochemical Control of Acromegaly. J Clin Endocrinol Metabolism 102:4218\u20134225. https:\/\/doi.org\/10.1210\/jc.2017-01210","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2940_CR25","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1210\/jc.2015-1917","volume":"100","author":"CM Reyes-Vidal","year":"2015","unstructured":"Reyes-Vidal CM, Mojahed H, Shen W, Jin Z, Arias-Mendoza F, Fernandez JC et al (2015) Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment. J Clin Endocrinol Metabolism 100:2946\u20132955. https:\/\/doi.org\/10.1210\/jc.2015-1917","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2940_CR26","doi-asserted-by":"publisher","first-page":"bvad028","DOI":"10.1210\/jendso\/bvad028","volume":"7","author":"AP Kuker","year":"2023","unstructured":"Kuker AP, Shen W, Jin Z, Chen J, Bruce JN, Freda PU (2023) Long-term Outcome of Body Composition, Ectopic Lipid, and Insulin Resistance Changes With Surgical Treatment of Acromegaly. J Endocr Soc 7:bvad028. https:\/\/doi.org\/10.1210\/jendso\/bvad028","journal-title":"J Endocr Soc"},{"key":"2940_CR27","doi-asserted-by":"publisher","first-page":"bvab004","DOI":"10.1210\/jendso\/bvab004","volume":"5","author":"AP Kuker","year":"2021","unstructured":"Kuker AP, Shen W, Jin Z, Singh S, Chen J, Bruce JN et al (2021) Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly. J Endocr Soc 5:bvab004. https:\/\/doi.org\/10.1210\/jendso\/bvab004","journal-title":"J Endocr Soc"},{"key":"2940_CR28","doi-asserted-by":"publisher","unstructured":"Szendroedi J, Zwettler E, Schmid AI, Chmelik M, Pacini G, Kacerovsky G et al (2008) Reduced Basal ATP Synthetic Flux of Skeletal Muscle in Patients with Previous Acromegaly. Calbet JAL, editor. PLoS ONE 3:e3958. https:\/\/doi.org\/10.1371\/journal.pone.0003958","DOI":"10.1371\/journal.pone.0003958"},{"key":"2940_CR29","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1210\/jc.2011-2681","volume":"97","author":"M Madsen","year":"2012","unstructured":"Madsen M, Krusenstjerna-Hafstr\u00f8m T, M\u00f8ller L, Christensen B, Vendelbo MH, Pedersen SB et al (2012) Fat Content in Liver and Skeletal Muscle Changes in a Reciprocal Manner in Patients with Acromegaly during Combination Therapy with a Somatostatin Analog and a GH Receptor Antagonist: A Randomized Clinical Trial. J Clin Endocrinol Metabolism 97:1227\u20131235. https:\/\/doi.org\/10.1210\/jc.2011-2681","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2940_CR30","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1210\/jc.2014-2242","volume":"99","author":"Y Winhofer","year":"2014","unstructured":"Winhofer Y, Wolf P, Kr\u0161\u0161\u00e1k M, Wolfsberger S, Tura A, Pacini G et al (2014) No Evidence of Ectopic Lipid Accumulation in the Pathophysiology of the Acromegalic Cardiomyopathy. J Clin Endocrinol Metabolism 99:4299\u20134306. https:\/\/doi.org\/10.1210\/jc.2014-2242","journal-title":"J Clin Endocrinol Metabolism"},{"key":"2940_CR31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s12020-018-1742-x","volume":"62","author":"T Xie","year":"2018","unstructured":"Xie T, Ding H, Xia M, Zhang X, Sun W, Liu T et al (2018) Dynamic changes in the distribution of facial and abdominal adipose tissue correlated with surgical treatment in acromegaly. Endocrine 62:552\u2013559. https:\/\/doi.org\/10.1007\/s12020-018-1742-x","journal-title":"Endocrine"},{"key":"2940_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/ejendo\/lvac014","volume":"188","author":"MC Arlien-S\u00f8borg","year":"2023","unstructured":"Arlien-S\u00f8borg MC, Madsen MA, Dal J, Krusenstjerna-Hafstr\u00f8m T, Ringgaard S, Skou N et al (2023) Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment. Eur J Endocrinol 188:78\u201385. https:\/\/doi.org\/10.1093\/ejendo\/lvac014","journal-title":"Eur J Endocrinol"},{"key":"2940_CR33","doi-asserted-by":"publisher","first-page":"e134638","DOI":"10.1172\/jci.insight.134638","volume":"5","author":"P Fellinger","year":"2020","unstructured":"Fellinger P, Wolf P, Pfleger L, Krumpolec P, Krssak M, Klavins K et al (2020) Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly. JCI Insight 5:e134638. https:\/\/doi.org\/10.1172\/jci.insight.134638","journal-title":"JCI Insight"},{"key":"2940_CR34","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1210\/clinem\/dgaf155","volume":"110","author":"C Baumgartner","year":"2025","unstructured":"Baumgartner C, Metz M, Beghini M, Pfleger L, Tosin A, Koldyka O et al (2025) Growth Hormone Promotes Hepatic Triglyceride Export in Humans. J Clin Endocrinol Metab 110:3420\u20133429. https:\/\/doi.org\/10.1210\/clinem\/dgaf155","journal-title":"J Clin Endocrinol Metab"},{"key":"2940_CR35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, Ratziu V, Bugianesi E, Francque S et al (2024) EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"2940_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00330-010-1905-5","volume":"21","author":"AE Bohte","year":"2011","unstructured":"Bohte AE, Van Werven JR, Bipat S, Stoker J (2011) The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol 21:87\u201397. https:\/\/doi.org\/10.1007\/s00330-010-1905-5","journal-title":"Eur Radiol"},{"key":"2940_CR37","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12072-021-10143-4","volume":"15","author":"T Ito","year":"2021","unstructured":"Ito T, Ishigami M, Zou B, Tanaka T, Takahashi H, Kurosaki M et al (2021) The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995\u20132040. Hepatol Int 15:366\u2013379. https:\/\/doi.org\/10.1007\/s12072-021-10143-4","journal-title":"Hepatol Int"},{"key":"2940_CR38","doi-asserted-by":"publisher","first-page":"155589","DOI":"10.1016\/j.metabol.2023.155589","volume":"144","author":"MC V\u00e1zquez-Borrego","year":"2023","unstructured":"V\u00e1zquez-Borrego MC, Del R\u00edo-Moreno M, Pyatkov M, Sarmento-Cabral A, Mahmood M, Pelke N et al (2023) Direct and systemic actions of growth hormone receptor (GHR)-signaling on hepatic glycolysis, de novo lipogenesis and insulin sensitivity, associated with steatosis. Metabolism 144:155589. https:\/\/doi.org\/10.1016\/j.metabol.2023.155589","journal-title":"Metabolism"},{"key":"2940_CR39","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1210\/clinem\/dgad206","volume":"108","author":"P Fellinger","year":"2023","unstructured":"Fellinger P, Beiglb\u00f6ck H, Semmler G, Pfleger L, Smajis S, Baumgartner C et al (2023) Increased GH\/IGF-I Axis Activity Relates to Lower Hepatic Lipids and Phosphor Metabolism. J Clin Endocrinol Metab 108:e989\u2013e997. https:\/\/doi.org\/10.1210\/clinem\/dgad206","journal-title":"J Clin Endocrinol Metab"},{"key":"2940_CR40","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41574-024-00993-x","volume":"20","author":"D Esposito","year":"2024","unstructured":"Esposito D, Boguszewski CL, Colao A, Fleseriu M, Gatto F, J\u00f8rgensen JOL et al (2024) Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management. Nat Rev Endocrinol 20:541\u2013552. https:\/\/doi.org\/10.1038\/s41574-024-00993-x","journal-title":"Nat Rev Endocrinol"},{"key":"2940_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11102-024-01422-y","volume":"27","author":"F Gatto","year":"2024","unstructured":"Gatto F, Milioto A, Corica G, Nista F, Campana C, Arecco A et al (2024) Temporal and masseter muscle evaluation by MRI provides information on muscle mass and quality in acromegaly patients. Pituitary 27:507\u2013517. https:\/\/doi.org\/10.1007\/s11102-024-01422-y","journal-title":"Pituitary"},{"key":"2940_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11102-024-01487-9","volume":"28","author":"Y Kinoshita","year":"2024","unstructured":"Kinoshita Y, Taguchi A, Yamasaki F, Onishi S, Tominaga A, Horie N (2024) Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests. Pituitary 28:4. https:\/\/doi.org\/10.1007\/s11102-024-01487-9","journal-title":"Pituitary"},{"key":"2940_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1210\/clinem\/dgaa859","volume":"106","author":"C Campana","year":"2021","unstructured":"Campana C, Cocchiara F, Corica G, Nista F, Arvigo M, Amar\u00f9 J et al (2021) Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment. J Clin Endocrinol Metab 106:789\u2013801. https:\/\/doi.org\/10.1210\/clinem\/dgaa859","journal-title":"J Clin Endocrinol Metab"},{"key":"2940_CR44","doi-asserted-by":"publisher","first-page":"G342","DOI":"10.1152\/ajpgi.00413.2004","volume":"289","author":"S Fruchtman","year":"2005","unstructured":"Fruchtman S, Simmons JG, Michaylira CZ, Miller ME, Greenhalgh CJ, Ney DM et al (2005) Suppressor of cytokine signaling-2 modulates the fibrogenic actions of GH and IGF-I in intestinal mesenchymal cells. Am J Physiol Gastrointest Liver Physiol 289:G342\u2013350. https:\/\/doi.org\/10.1152\/ajpgi.00413.2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2940_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1055\/a-2015-1359","volume":"43","author":"M Oxley","year":"2023","unstructured":"Oxley M, Francis H, Sato K (2023) Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies. Semin Liver Dis 43:24\u201330. https:\/\/doi.org\/10.1055\/a-2015-1359","journal-title":"Semin Liver Dis"},{"key":"2940_CR46","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","volume":"358","author":"AJ van der Lely","year":"2001","unstructured":"van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754\u20131759. https:\/\/doi.org\/10.1016\/S0140-6736(01)06844-1","journal-title":"Lancet"},{"key":"2940_CR47","doi-asserted-by":"publisher","unstructured":"Gatto F, Arecco A, Amar\u00f9 J, Arvigo M, Campana C, Milioto A et al (2025) Differential Impact of Medical Therapies for Acromegaly on Glucose Metabolism. Int J Mol Sci publisher 26. https:\/\/doi.org\/10.3390\/ijms26020465","DOI":"10.3390\/ijms26020465"},{"key":"2940_CR48","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11102-025-01629-7","volume":"29","author":"F Gatto","year":"2026","unstructured":"Gatto F, Arecco A, De Alcubierre D, De Simone M, Gentiluomo R, Lanzi V et al (2026) Gender differences in the glycometabolic and cardiovascular features of acromegaly. Pituitary 29:34. https:\/\/doi.org\/10.1007\/s11102-025-01629-7","journal-title":"Pituitary"},{"key":"2940_CR49","doi-asserted-by":"publisher","first-page":"101790","DOI":"10.1016\/j.beem.2023.101790","volume":"37","author":"NA Tritos","year":"2023","unstructured":"Tritos NA (2023) Growth hormone replacement in adults with cured acromegaly: Efficacy and safety. Best Pract Res Clin Endocrinol Metab 37:101790. https:\/\/doi.org\/10.1016\/j.beem.2023.101790","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2940_CR50","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1210\/jc.2009-1611","volume":"95","author":"KK Miller","year":"2010","unstructured":"Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C et al (2010) Growth Hormone Deficiency after Treatment of Acromegaly: A Randomized, Placebo-Controlled Study of Growth Hormone Replacement. J Clin Endocrinol Metab 95:567\u2013577. https:\/\/doi.org\/10.1210\/jc.2009-1611","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02940-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02940-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:01:15Z","timestamp":1793397675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02940-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["2940"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02940-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.S., M. P.-W., E. A.-M., A.S. received honoraria from Recordati, Novartis and Ipsen for lectures, writing and educational events. Z. L.-R. Has received honoraria from Novo Nordisk and Eli Lilly for educational events.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}